智通财经APP获悉，致力于开发活体生物药物以激发免疫反应的临床阶段癌症生物技术公司 Salspera(TKVA.US)，周一披露了其美股首次公开募股(IPO)条款。 Salspera旨在开发一类全新的免疫疗法用于治疗实体瘤，该公司将其命名为"活体生物药"，即经过基因 改造、能够在肿瘤微环境内表达特定抗肿瘤因子的生物制剂。 其先导项目Saltikva是一种经过减毒改造的鼠伤寒沙门氏菌菌株，无毒且可口服给药。该菌株经工程化 设计，可表达人白细胞介素-2基因(即Salmonella-IL2)，这可能有助于增加肿瘤微环境及外周血中NK细 胞和CD8+细胞毒性T细胞的数量。公司目前主要针对胰腺癌，并已完成一项针对IV期转移性胰腺癌患 者的II期试验。 Salspera成立于2017年，计划在纳斯达克上市，股票代码为TKVA。Kingswood资本市场担任该交易的独 家账簿管理人。 这家总部位于马萨诸塞州剑桥市的公司计划通过发行570万股股票(发行价区间为每股14至16美元)筹集 8500万美元资金。 ...

Group 1 - The launch of Zhuhai Zhongke Innovation Technology Park and the signing of 11 major projects aim to inject strong development momentum into the Guangdong-Hong Kong-Macao Greater Bay Area's innovation ecosystem [1][2] - The technology park, covering approximately 220,000 square meters, will focus on emerging industries such as artificial intelligence, robotics, biomedical engineering, and integrated circuits, planning to accommodate over 100 high-tech enterprises and form a high-end industrial cluster of 500-1,000 people [1][3] - The expected output value of incubated enterprises is projected to be no less than 2 billion yuan, establishing a benchmark platform for technology achievement transformation and industrial incubation in the Greater Bay Area [1] Group 2 - The "Chinese Academy of Sciences Shenzhen Advanced Institute Achievement Supermarket Zhuhai Center" was launched simultaneously, featuring over 300 selected high-quality achievements across seven major fields, including medical devices and artificial intelligence [2] - The center aims to visualize information such as technical parameters and application scenarios, facilitating the connection between scientific research achievements and industrial needs, thereby accelerating the deep integration of the innovation chain and the industrial chain [2] - The 2025 Zhuhai "Innovation Cup" competition in the "Cloud Smart City" and "Biomedicine" sectors has officially started, attracting numerous enterprise and team projects to showcase and incubate innovative talents and quality projects [2] Group 3 - The 11 major projects signed focus on strategic emerging industries such as biomedicine, medical devices, artificial intelligence, and new materials, with significant breakthroughs in key technologies like gene editing and viral vector production [3] - The projects will leverage the park's unique incubation ecosystem, creating a full-chain industrial loop from research breakthroughs to product iteration and market expansion [3] - The goal is to establish a virtuous development pattern where research, transformation, and benefits occur within the park [3] Group 4 - The launch of Zhuhai Zhongke Innovation Technology Park is a significant milestone for the collaboration between Shenzhen and Zhuhai in scientific innovation [4] - The park will establish a cross-regional collaborative model of "Shenzhen R&D + Zhuhai Transformation," promoting rapid market entry of scientific achievements [4] - The Shenzhen Advanced Institute has already established several major transformation projects in Zhuhai and will continue to supply innovative resources to help Zhuhai become a new highland for technology achievement transfer and transformation in the Greater Bay Area [4]